FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a pharmaceutical composition containing at least 95% of ethyl eucosapentaenoate (ethyl-EPA) of the total amount of fatty acids present in the composition enclosed in a capsule shell containing gelatin in an amount of from 50% to 70 % by weight of non-aqueous components, but not containing chemically modified gelatin, glycerin in an amount of 5% to 15% by weight of non-aqueous components, sorbitol in an amount of 15% to 25% by weight of non-aqueous components, maltitol in an amount of 3% to 10% from the mass of non-aqueous components and purified water.
EFFECT: technical result is greater weakening or preventing the oxidation of ethyl-EPA in the composition of the pharmaceutical composition enclosed in the capsule shell according to the invention than with the standard type IIa capsule shell.
12 cl, 3 dwg, 4 tbl, 4 ex
